Rheumatoid Arthritis: What It Is, Its Stages, and How It Differs From Other Arthritis

Short Answer

Rheumatoid arthritis (RA) is an autoimmune, inflammatory disease: your immune system targets the synovium — the thin lining inside your joints — so the joint can become painful, swollen, warm, and stiff; if that inflammation keeps running untreated, it can damage cartilage and bone. It is “a chronic autoimmune disease characterized by synovial joint inflammation and different system involvement,” which is why RA is more than a “joint” disease. The same inflammatory process can show up as fatigue and can involve tissues beyond the joints, including the lungs, heart, eyes, blood, and skin. (Nutrients 2026, PMC12900012)

The cleanest difference between RA and osteoarthritis is the driver. Osteoarthritis is mostly a degenerative, wear-and-tear joint condition that becomes more common with age; RA is immune-driven inflammation that often affects joints on both sides of the body and is typically worse after rest or in the morning. But the symptoms can blur, which is why RA and osteoarthritis are “prevalent joint diseases with overlapping clinical manifestations but distinct pathogenesis and treatment strategies.” Getting that distinction right matters, because the treatments are not the same. (Frontiers in Medicine 2026, PMC13111120)

There is no single “yes/no” test for RA. Doctors diagnose the pattern: your symptoms, joint exam, blood markers such as ESR or CRP, immune markers such as rheumatoid factor and anti-CCP, and imaging such as X-ray, ultrasound, or MRI when needed. Treatment is time-sensitive because disease-modifying antirheumatic drugs (DMARDs) can slow the disease process and reduce joint damage; early treatment can help prevent symptoms from worsening and protect long-term joint function. (NHS)

Rheumatoid arthritis at a glance

• What it is — Rheumatoid arthritis (RA) is an autoimmune disease: your immune system misreads your own joint tissue as a threat and keeps inflammation running when it should shut off. In clinical terms, it is “an autoimmune disorder associated with chronic inflammation, progressive deformities of the joints, and limited mobility” (Frontiers in Medicine 2025, PMC12832795).

• Core mechanism — The main target is the synovium — the thin lining inside a joint. Immune cells drive swelling there; over time, the lining thickens, forms inflammatory pannus, and can invade cartilage and bone. RA is “a chronic autoimmune disease characterized by synovial joint inflammation and different system involvement” (Nutrients 2026, PMC12900012).

• Not the same as — RA is not osteoarthritis. Osteoarthritis is more about mechanical cartilage breakdown and joint wear; RA is immune-driven inflammation that attacks the joint lining and can erode bone. That is why RA and OA have “distinct pathogenesis and treatment strategies” (Frontiers in Medicine 2026, PMC13111120).

• Systemic reach — RA can feel like “joint disease,” but it is a whole-body inflammatory condition. The same immune activity that hurts your hands, wrists, feet, or knees can also show up as fatigue, low-grade fever, appetite changes, or problems involving the heart, lungs, blood, nerves, eyes, or skin. It is “a chronic autoimmune disease frequently accompanied by cardiovascular, respiratory, skeletal, psychiatric, and neoplastic comorbidities” (Healthcare 2026, PMC12840766).

• Who it affects — RA can start at almost any age, but it is more common in women. NIAMS describes RA as affecting about two to three times as many women as men; NIH also notes that autoimmune diseases as a group are more common in women. (NIAMS)

• The 4 stages — The “4 stages” are a useful damage map, not a guaranteed path for every person. The classic staging frame moves from early inflammation without destructive X-ray changes, to cartilage and bone damage, to joint deformity, and finally to bony or fibrous ankylosis — joint fusion. In body terms: synovitis can become pannus, pannus can damage cartilage and bone, and late structural damage can severely limit movement. (StatPearls / NCBI Bookshelf)

• Diagnosis — Diagnosis is clinical plus lab and imaging evidence. Your clinician looks at your symptom pattern, joint exam, inflammatory markers, antibodies such as rheumatoid factor or anti-CCP, and imaging when needed; there is no single test that proves or rules out RA by itself. (NIAMS)

• ICD-10 code — M06.9 is used for rheumatoid arthritis, unspecified. Seropositive RA falls under the M05.\ family; M05.9* is rheumatoid arthritis with rheumatoid factor, unspecified. (CDC/NCHS ICD-10-CM)

• Treatment — DMARDs are the treatment backbone because they target the disease process, not just pain. Current ACR guidance covers conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs; the goal is to control inflammation early enough to protect function and reduce long-term joint damage. Specific drugs and doses are always decided by a clinician. (2021 ACR guideline)

What rheumatoid arthritis is — and why it is more than a joint disease

Rheumatoid arthritis is an autoimmune disease, which means the immune system stops recognizing some of the body’s own tissue as “self.” Instead of only defending you from infections, immune cells and inflammatory signals turn toward the joints. The main target is the synovium — the thin lining inside a joint that normally helps movement feel smooth. In RA, that lining becomes inflamed, swollen, and biologically active; over time, the same inflammatory process can damage cartilage, bone, tendons, and the shape of the joint itself. RA is “a chronic autoimmune disease characterized by synovial joint inflammation and different system involvement” — and that second half matters, because RA is not confined to the joints. (Nutrients 2026, PMC12900012) Described more plainly, it is “an autoimmune disorder associated with chronic inflammation, progressive deformities of the joints, and limited mobility.” (Frontiers in Medicine 2025, PMC12832795)

That is why RA can feel bigger than “joint pain.” The same immune misfiring that makes your fingers stiff in the morning can also create a whole-body inflammatory load: fatigue, low energy, brain fog, sleep disruption, and a sense that your body is running hot even when one joint is the loudest symptom. Clinically, RA is “a chronic autoimmune disease frequently accompanied by cardiovascular, respiratory, skeletal, psychiatric, and neoplastic comorbidities,” which means doctors have to think beyond swollen knuckles and painful knees. (Healthcare 2026, PMC12840766) Mayo Clinic and Johns Hopkins both describe RA as a disease that can affect non-joint parts of the body, including the heart, lungs, skin, blood vessels, and other organs. (Mayo Clinic)

The heart-and-blood-vessel connection is one of the clearest examples of this systemic footprint. Chronic inflammation can irritate blood vessels, worsen endothelial function, and interact with traditional cardiovascular risks; research consistently treats cardiovascular disease as an important RA comorbidity rather than a separate afterthought. One recent RA/SLE cardiovascular-risk study states that “cardiovascular disease (CVD) events are increased in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).” (Clinical Rheumatology 2026, PMC12833825) Older and newer reviews also link RA’s systemic inflammation with higher cardiovascular burden, which is why prevention, monitoring, and inflammation control matter even when the most visible symptoms are in the hands or feet. (PMC6889899)

So the practical takeaway is simple: RA is managed as an immune-system disease with joint symptoms, not as ordinary wear-and-tear arthritis. That is why rheumatologists look at pain, swelling, stiffness, mobility, fatigue, lab markers, imaging, medications, comorbidities, and your day-to-day function together. The goal is not only to make a painful joint quieter today. It is to reduce the chronic inflammation “that results in considerable physical and psychological symptoms,” protect movement, and lower the chance that RA keeps spreading its effects through the rest of your body. (Nutrients 2026, PMC12900012)

What are the 4 stages of rheumatoid arthritis?

RA can be progressive if inflammation stays active. Clinicians and patient-education resources often explain that progression in four stages: early inflammation around the joint, cartilage damage, bone damage, and finally severe loss of joint structure or function. The labels below are plain-English labels for that framework; formal ACR-style staging is usually described by what X-rays show, from no destructive changes to cartilage and bone destruction, deformity, and ankylosis. (Cleveland Clinic)

• Stage 1 — Early RA (synovitis). This is where the immune system is already irritating the synovium — the thin lining inside the joint — so the joint may feel stiff, swollen, warm, or tender. But the key point is what is not there yet: X-rays typically do not show destructive bone changes at this stage. (Cleveland Clinic)

• Stage 2 — Moderate RA (pannus and cartilage). As inflammation keeps running, the synovium can thicken into invasive inflammatory tissue called pannus. That tissue is not just “swelling”; it can start damaging cartilage, the smooth shock-absorbing surface that helps the joint move. This is when stiffness may become harder to shake off and range of motion can start to shrink. (Cleveland Clinic)

• Stage 3 — Severe RA (bone erosion). By this stage, inflammation has reached the bone. The joint may hurt more, move less, and begin to look or feel unstable because cartilage and bone destruction can change the joint’s shape and mechanics. Muscle around the joint may also weaken because pain and poor movement make you use that area less. (Cleveland Clinic)

• Stage 4 — End-stage RA (fusion/ankylosis). In advanced RA, the active inflammation may be less obvious than before, but the joint can keep losing function because the structure has already been badly damaged. Formal staging describes this stage as bony or fibrous ankylosis — a fusion or stiffening of the joint — along with the severe destructive changes seen earlier. (StatPearls / NCBI Bookshelf)

The practical point: modern RA treatment aims to catch and control the disease early, before structural damage builds up. Once joint damage happens, it generally cannot be reversed, so early diagnosis, treatment, and regular monitoring matter — not because every person moves through all four stages, but because the goal is to keep you from getting there. Between-visit tracking of how your body is coping can add context here, especially when symptoms are changing — see §6. (NIAMS)

How rheumatoid arthritis differs from other kinds of arthritis

"Arthritis" is an umbrella term, and RA is only one member. That matters because the “why” inside the joint is different — and when the biology is different, the treatment plan is different too.

RA vs. osteoarthritis (OA). This is the most common mix-up. OA is a degenerative, wear-and-tear condition: the cushioning cartilage in the joint wears down over time, so pain often shows up during or after movement and stiffness may be most noticeable after waking or after being inactive. RA is autoimmune: your immune system attacks your own tissues, especially the synovium, the lining inside the joint. The two are “prevalent joint diseases with overlapping clinical manifestations but distinct pathogenesis and treatment strategies,” which is exactly why “accurate molecular discrimination between RA and OA is important” (Frontiers in Medicine 2026, PMC13111120). A rough rule of thumb: RA often affects the same joints on both sides of the body and comes with morning or after-rest stiffness that can last longer than 30 minutes; OA tends to feel more mechanical, with symptoms tied more closely to joint use. (Mayo Clinic)

RA and lupus (SLE). Both are systemic autoimmune diseases, so they can look similar early on: joint pain, swelling, stiffness, fatigue, flares. They also share elevated cardiovascular risk, since “cardiovascular disease (CVD) events are increased in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)” (Clinical Rheumatology 2026, PMC12833825). But they are not the same diagnosis. RA usually settles most visibly in the synovium and often follows a symmetrical joint pattern; lupus can inflame many organs and tissues — skin, kidneys, heart, lungs, blood cells, brain — and is worked up with a different antibody pattern, including ANA and, when appropriate, anti-dsDNA, anti-Smith, and antiphospholipid antibodies. (NIAMS)

RA and psoriatic arthritis — and the "5 types." Psoriatic arthritis (PsA) is another immune-mediated inflammatory arthritis, usually linked to psoriasis, but it does not behave exactly like RA. RA’s core target is the joint lining; PsA can involve peripheral joints, distal finger or toe joints, the spine and sacroiliac joints, entheses where tendons and ligaments attach, and whole-digit swelling called dactylitis. The classic Moll and Wright classification describes five PsA subtypes: asymmetric oligoarticular arthritis, symmetric polyarticular arthritis, distal arthritis with prominent distal interphalangeal involvement, arthritis mutilans, and spondyloarthritis. That is why PsA can sometimes mimic RA — especially the symmetric polyarticular pattern — while still pointing to a different disease process and a different treatment conversation. (StatPearls / NCBI Bookshelf)

Autoimmune arthritis of all kinds sits in one family, but each condition has its own fingerprint. A review of autoimmune disease lists that “Common types include systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis” among others — a reminder that the shared thread is immune dysregulation, not the specific joint. (Research 2026, PMC12868559)

How is rheumatoid arthritis diagnosed?

There is no single test that confirms RA on its own. A rheumatologist is looking for a body-wide pattern: where your joints hurt or swell, whether the stiffness is worse after rest, what the joint exam shows, what your blood markers say, and whether imaging shows inflammation or damage. MedlinePlus puts it plainly: there’s “no single test” for rheumatoid arthritis, and the CDC describes diagnosis as a mix of physical exam, X-rays, lab tests, and health history. (MedlinePlus)

Blood markers. The standard workup relies on antibody and inflammation tests. As a recent US practice review put it, “Diagnostic tests include conventional markers (rheumatoid factor and anti-cyclic citrullinated peptide)” — the two classic RA antibodies — alongside inflammation measures such as ESR and CRP. Anti-CCP/ACPA is especially useful because it is more specific for RA than rheumatoid factor, but neither test is a perfect yes-or-no switch. (ACR Open Rheumatology 2026, PMC12927980)

Not everyone with RA tests positive, though. RA is “an autoimmune disease for which better biomarkers are needed, especially in seronegative cases,” meaning some patients have RA despite negative antibody tests; recent reviews commonly describe seronegative RA as roughly 20–30% of cases. General inflammation from a routine blood count can also track the disease, since “CBC-derived inflammatory indices are elevated in RA and reflect systemic inflammation.” That does not mean a CBC diagnoses RA by itself. It means the immune system can leave a measurable footprint in ordinary blood counts, especially when RA is active. (Frontiers in Immunology 2026, PMC12867769)

Monitoring over time. Once RA is diagnosed, the question changes from “is this RA?” to “how active is it right now, and is treatment controlling the inflammation?” That’s why clinicians repeat symptoms, joint counts, ESR/CRP, and sometimes additional panels over time; “Monitoring tests include the Vectra tests” among the tools used to gauge disease activity. The point is trend, not one isolated number. If your swelling, pain, sleep, fatigue, and labs all move in the same direction, your care team gets a clearer read on whether the flare is calming down or building. (ACR Open Rheumatology 2026, PMC12927980)

Classification criteria and coding. RA is also standardized through the 2010 ACR/EULAR classification criteria. In those criteria, “definite RA” requires confirmed synovitis in at least one joint, no better alternative diagnosis, and a score of 6 or more out of 10 across four domains: joint involvement, serology, acute-phase reactants, and symptom duration. These criteria help doctors and researchers speak the same language, but your rheumatologist still interprets them in the context of your actual body and history. (2010 ACR/EULAR criteria)

For medical records and insurance in the US, RA is coded with ICD-10-CM, the diagnosis-code system maintained by CDC’s National Center for Health Statistics. In the CDC ICD-10-CM index, rheumatoid arthritis maps to M06.9 when unspecified; seropositive RA maps to M05.9, while more specific M05 and M06 codes can describe organ involvement or the exact joint site. (CDC/NCHS ICD-10-CM)

How rheumatoid arthritis is treated

There is no cure that switches RA off for good. But RA is highly treatable, and the reason early care matters is physical: inflammation inside the synovium can keep calling immune cells into the joint, thickening the lining, irritating pain nerves, and — over time — damaging cartilage and bone. Modern RA care tries to interrupt that process before later-stage damage sets in. The target is usually low disease activity first, and remission when possible, using a treat-to-target approach with regular reassessment rather than “wait and see.” The 2021 American College of Rheumatology guideline says RA needs early evaluation, diagnosis, and management, and that treatment decisions should be revisited based on response and tolerability. (2021 ACR guideline)

The backbone is a class of drugs called DMARDs — disease-modifying antirheumatic drugs. These are not just painkillers. They are used because RA is an immune-driven disease, and symptom relief alone does not reliably protect the joint from ongoing inflammatory damage. As one 2026 review summarizes, “Treatment of RA includes conventional and biological disease-modifying antirheumatic drugs (DMARDs),” plus “symptomatic response modifiers, like corticosteroids and non-steroidal antirheumatic drugs” for symptom relief. (Nutrients 2026, PMC12900012)

For some people, the first plan works well. For others, RA keeps breaking through: pain, swelling, fatigue, stiffness, abnormal inflammatory markers, or imaging changes may persist even after more advanced treatment steps. That is why rheumatology care is iterative. If you are not at target, your clinician may adjust the plan, monitor safety labs, consider other drug classes, and account for infection risk, heart and lung history, pregnancy plans, kidney or liver function, other medications, and what side effects you can realistically live with. Some patients still have hard-to-treat disease — “a considerable proportion of patients exhibit refractory disease” and move through multiple advanced therapies. (ACR Open Rheumatology 2026, PMC12893821)

Specific drug choices, combinations, monitoring, and the decision to escalate to biologic or targeted synthetic DMARDs are individualized medical decisions made by a rheumatologist, based on disease activity, other conditions, safety risks, lab monitoring, and shared decision-making. This article does not recommend any specific drug, dose, or regimen. For a fuller class-by-class walkthrough of RA medications — including DMARD tiers, methotrexate, biologics, JAK inhibitors, and safety monitoring — see our dedicated guide on [rheumatoid arthritis treatment](/rheumatoid-arthritis/treatment/). (2021 ACR guideline)

Medication is the disease-modifying layer. Everyday management is the load-management layer. Gentle movement, physical or occupational therapy, joint protection, sleep, and stress recovery do not replace DMARDs, but they can help you preserve function and reduce the strain your nervous system and inflamed joints have to absorb each day. The 2022 ACR guideline strongly recommends consistent exercise over no exercise for RA, while emphasizing that exercise type, intensity, and timing should be tailored to the person, especially when joints are actively inflamed or damaged. (2022 ACR integrative guideline)

That day-to-day layer is where wearable tracking can add context between rheumatology visits. It will not diagnose a flare or decide treatment. But patterns in sleep, resting heart rate, HRV, activity, and recovery can help you notice when your body is taking on more inflammatory or stress load than usual — useful context to bring into the medical plan, especially if symptoms are changing before your next appointment.

Rheumatoid arthritis, flares, and what your body signals show

RA symptoms come in flares — stretches when inflammation gets louder and pain, stiffness, swelling, and fatigue climb — followed by calmer periods with less or no swelling and pain. That “roller coaster” is not only something you feel in your joints. When immune activity rises, your autonomic nervous system, movement, recovery, and sleep can shift too. In plain language: your body may start spending more energy on inflammation before the flare fully announces itself. (Mayo Clinic)

A 2025 study using consumer wearables found that in RA, “Circadian features of HRV differentiated inflammatory and symptomatic flares from remission,” and strikingly that “All metrics were altered up to 4 weeks prior to inflammatory and symptomatic flare development.” Participants in that study “wore an Apple Watch (n = 35), Fitbit (n = 17), or Oura Ring (n = 3) collecting heart rate (HR), resting heart rate (RHR), heart rate variability (HRV), and steps.” Earlier work pointed the same way, noting that “Flares in rheumatoid arthritis (RA) and axial spondyloarthritis (SpA) may influence physical activity.” In a 3-month tracker study of RA and axial spondyloarthritis, persistent flares lasting more than 3 days were associated with a measurable drop in daily physical activity. (Scientific Reports 2025, PMC12770556)

Where Welltory fits. Welltory is not a diagnostic tool and does not diagnose, stage, predict, or treat RA. What it can give you is a pattern lens on signals researchers are studying in relation to RA activity: heart rate variability, resting heart rate, sleep quality, stress load, and movement trends from the wearable you already use. For someone living with an RA diagnosis, those trends can make the blurry part of a flare more concrete. Maybe your resting heart rate has been creeping up. Maybe HRV has been lower than your usual baseline. Maybe sleep and recovery have been poor for several nights before your joints feel worse. One day like that does not mean “flare.” A repeated pattern over weeks is more useful.

The practical value is not self-diagnosis. It is context. If your symptoms change, a log of pain, fatigue, sleep, HRV, resting heart rate, steps, stress, and medication timing can help you have a more precise conversation with your rheumatologist. Your clinician still owns the medical decisions: diagnosis, disease activity assessment, lab testing, imaging, staging, medication changes, and flare treatment. Welltory’s role is to help you notice what your body has been doing between appointments — not to replace the appointment.

How we made it

Made with AI tools, then edited, fact-checked, and medically reviewed by the Welltory team.

The wearable-device findings on heart rate, resting heart rate, HRV, and steps around RA flares come from independent published research, not from Welltory's own user data; Welltory offers a way to track those same signals over time as personal context, not a diagnosis.

Discounts for blog readers: up to 36% off

See what affects your energy, stress, sleep, and daily state with Welltory

Explore your data